Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited
Markus Diefenhardt(Goethe University Frankfurt), Emmanouil Fokas(Düsseldorf University Hospital), Claus Rödel(Goethe University Frankfurt), Pompiliu Piso(Krankenhaus Barmherzige Brüder), Simon Kirste(University of Freiburg), Wolf O. Bechstein(Unknown), Ralf‐Dieter Hofheinz(University of Mannheim), Thomas Kuhnt(Leipzig University), Anke Schlenska‐Lange(Krankenhaus Barmherzige Brüder), Guido Hildebrandt(University of Rostock), Michael Ghadimi(Universitätsmedizin Göttingen)
Cited by 12
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960